BR112016022607B8 - Pó e método para aprimorar a aplicação tópica de minoxidil - Google Patents

Pó e método para aprimorar a aplicação tópica de minoxidil

Info

Publication number
BR112016022607B8
BR112016022607B8 BR112016022607A BR112016022607A BR112016022607B8 BR 112016022607 B8 BR112016022607 B8 BR 112016022607B8 BR 112016022607 A BR112016022607 A BR 112016022607A BR 112016022607 A BR112016022607 A BR 112016022607A BR 112016022607 B8 BR112016022607 B8 BR 112016022607B8
Authority
BR
Brazil
Prior art keywords
powder
active ingredient
topical application
minoxidil
capsule
Prior art date
Application number
BR112016022607A
Other languages
English (en)
Other versions
BR112016022607B1 (pt
Inventor
Sun Ying
M Wu Jeffrey
Fassih Ali
Original Assignee
Johnson & Johnson Consumer Inc
Chenango Zero Llc
Chenango Two Llc
Currahee Holding Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc, Chenango Zero Llc, Chenango Two Llc, Currahee Holding Company Inc filed Critical Johnson & Johnson Consumer Inc
Publication of BR112016022607B1 publication Critical patent/BR112016022607B1/pt
Publication of BR112016022607B8 publication Critical patent/BR112016022607B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/022—Powders; Compacted Powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/65—Characterized by the composition of the particulate/core
    • A61K2800/652—The particulate/core comprising organic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÕES E MÉTODO PARA MELHORAR A APLICAÇÃO TÓPICA DE UM AGENTE DE BENEFÍCIO BÁSICO. A presente invenção se refere a um pó que inclui partículas de núcleo/cápsula que têm um tamanho médio de partícula menor que 1000 mícrons, sendo que cada partícula contém um núcleo líquido que é substancialmente isento de água e inclui A) um líquido polar tendo um percentual de polaridade de superfície de ao menos 24%, um ingrediente ativo básico, e C) de cerca de 0,1% a cerca de 20%, em peso de ao menos um agente intensificador de solubilidade ácido que não é um ingrediente ativo; e uma cápsula que compreende partículas hidrofóbicas. O pó pode ser usado para administrar topicamente o ingrediente ativo a um ser humano ou animal.
BR112016022607A 2014-03-31 2015-03-10 Pó e método para aprimorar a aplicação tópica de minoxidil BR112016022607B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/230,565 2014-03-31
US14/230,565 US9474699B2 (en) 2014-03-31 2014-03-31 Compostions and methods for enhancing the topical application of a basic benefit agent
PCT/US2015/019589 WO2015153074A1 (en) 2014-03-31 2015-03-10 Compositions and methods for enhancing the topical application of a basic benefit agent

Publications (2)

Publication Number Publication Date
BR112016022607B1 BR112016022607B1 (pt) 2021-01-19
BR112016022607B8 true BR112016022607B8 (pt) 2022-08-30

Family

ID=52785154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022607A BR112016022607B8 (pt) 2014-03-31 2015-03-10 Pó e método para aprimorar a aplicação tópica de minoxidil

Country Status (8)

Country Link
US (1) US9474699B2 (pt)
EP (1) EP3125857B1 (pt)
CN (2) CN106456476B (pt)
BR (1) BR112016022607B8 (pt)
CA (1) CA2943368C (pt)
ES (1) ES2719575T3 (pt)
RU (1) RU2722783C2 (pt)
WO (1) WO2015153074A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9475709B2 (en) 2010-08-25 2016-10-25 Lockheed Martin Corporation Perforated graphene deionization or desalination
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US10980919B2 (en) 2016-04-14 2021-04-20 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US10418143B2 (en) 2015-08-05 2019-09-17 Lockheed Martin Corporation Perforatable sheets of graphene-based material
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
WO2014164621A1 (en) 2013-03-12 2014-10-09 Lockheed Martin Corporation Method for forming filter with uniform aperture size
CN105940479A (zh) 2014-01-31 2016-09-14 洛克希德马丁公司 使用宽离子场穿孔二维材料
CA2938305A1 (en) 2014-01-31 2015-08-06 Lockheed Martin Corporation Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
CA2942496A1 (en) 2014-03-12 2015-09-17 Lockheed Martin Corporation Separation membranes formed from perforated graphene
EA201790508A1 (ru) 2014-09-02 2017-08-31 Локхид Мартин Корпорейшн Мембраны гемодиализа и гемофильтрации на основе двумерного мембранного материала и способы их применения
EP3219773B1 (en) * 2014-11-11 2019-05-08 National Institute for Materials Science Film-forming composition including tannic acid derivative
JP2018530499A (ja) 2015-08-06 2018-10-18 ロッキード・マーチン・コーポレーション グラフェンのナノ粒子変性及び穿孔
JP2019511451A (ja) 2016-04-14 2019-04-25 ロッキード・マーチン・コーポレーション 浮遊法を用いてグラフェンシートを大判転写用に処理する方法
SG11201808961QA (en) 2016-04-14 2018-11-29 Lockheed Corp Methods for in situ monitoring and control of defect formation or healing
WO2017180139A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Two-dimensional membrane structures having flow passages
WO2017180141A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
US20190388355A1 (en) * 2016-12-01 2019-12-26 3M Innovative Properties Company Basic core material encapsulated in an inorganic shell suitable for use in biological carrier materials
US10596134B2 (en) * 2017-02-08 2020-03-24 Johnson & Johnson Consumer Inc. Compositions and methods for treating skin conditions using light and polycarboxylic acids
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
WO2019234633A1 (en) 2018-06-06 2019-12-12 3M Innovative Properties Company Two-part dental sealant, method of applying with a syringe device, and kit
CA3102288A1 (en) 2018-07-03 2020-01-09 The Procter & Gamble Company Method of treating a skin condition
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
WO2021247496A1 (en) 2020-06-01 2021-12-09 The Procter & Gamble Company Method of improving penetration of a vitamin b3 compound into skin
CN114788788B (zh) * 2022-05-09 2023-08-01 无锡知妍生物科技有限公司 一种二硫化硒包裹技术及二硫化硒洗发水
US11951082B2 (en) 2022-08-22 2024-04-09 Ford Therapeutics, Llc Composition of chlorhexidine

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1467023A1 (de) 1964-02-28 1969-01-23 Degussa Verfahren zur Inkorporierung von Wasser in feinst verteilter Kieselsaeure
DE2844052A1 (de) 1978-10-10 1980-04-30 Degussa Waessrige dispersion einer hydrophoben kieselsaeure
US5229076A (en) 1992-05-08 1993-07-20 Fagher Richard H Method for reducing polymer build-up in a polymerization reactor
US6174533B1 (en) 1997-05-23 2001-01-16 The Procter & Gamble Company Skin care compositions and method of improving skin appearance
AUPP310798A0 (en) 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
EP0964054A1 (en) 1998-06-11 1999-12-15 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Surface-active alkylurethanes of fructans
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US20020006418A1 (en) 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
FR2785539B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
JP2000309505A (ja) 1999-02-26 2000-11-07 Shiseido Co Ltd 粉末化粧料
US6290941B1 (en) 1999-11-23 2001-09-18 Color Access, Inc. Powder to liquid compositions
AU4473001A (en) * 2000-04-07 2001-10-30 Taisho Pharmaceutical Co Ltd Hair growth stimulant compositions with sustained action
US6413548B1 (en) 2000-05-10 2002-07-02 Aveka, Inc. Particulate encapsulation of liquid beads
EP1386599A4 (en) 2001-01-18 2009-07-22 Shiseido Co Ltd PROCESS FOR PRODUCING DRY WATER
US7914811B2 (en) * 2001-06-29 2011-03-29 Mcneil-Ppc, Inc. Brittle-coating, soft core dosage form
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20050220860A1 (en) 2002-04-15 2005-10-06 Kim Dong Y Stabilized pure vitamin-C in powder to liquid form using multi-encapsulation method
KR20050073445A (ko) * 2002-08-14 2005-07-13 이 아이 듀폰 디 네모아 앤드 캄파니 코팅된 다가불포화 지방산 함유 입자 및 코팅된 액상 제약함유 입자
US7477940B2 (en) 2003-06-30 2009-01-13 J&J Consumer Companies, Inc. Methods of administering an active agent to a human barrier membrane with galvanic generated electricity
US8734421B2 (en) 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
US7476222B2 (en) 2003-06-30 2009-01-13 Johnson & Johnson Consumer Companies, Inc. Methods of reducing the appearance of pigmentation with galvanic generated electricity
US7477939B2 (en) 2003-06-30 2009-01-13 Johnson & Johnson Consumer Companies, Inc. Methods of treating a wound with galvanic generated electricity
US20050084510A1 (en) 2003-10-20 2005-04-21 Carson John C. Water in oil formulations, method to prepare same, and personal care products formed using same
EP1694287A1 (de) 2003-12-01 2006-08-30 Degussa AG Verstreichbare kosmetische zubereitung mit hohem wassergehalt
US20050163811A1 (en) * 2004-01-23 2005-07-28 Richard Lee Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
US20060008485A1 (en) 2004-07-12 2006-01-12 Ferone James J Packaged cosmetic compositions and related methods
DE102004056862A1 (de) 2004-11-25 2006-06-14 Degussa Ag Pulverförmige, kosmetische Zubereitung mit hohem Wassergehalt
DE102005055226A1 (de) 2004-12-24 2006-07-13 Degussa Ag Lagerung pulverförmiger Stoffe mit hohem Wassergehalt
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20070154426A1 (en) 2006-01-05 2007-07-05 Hansen Angela M Powdered water cosmetic compositions and related methods
US7417020B2 (en) 2006-05-05 2008-08-26 Johnson & Johnson Consumer Companies, Inc. Compositions comprising low-DP polymerized surfactants and methods of use thereof
US20080038557A1 (en) 2006-08-08 2008-02-14 The Procter & Gamble Company Process for making collapsible water-containing capsules
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US7704533B2 (en) 2006-12-13 2010-04-27 J&J Consumer Companies, Inc. Compositions and methods of inducing hair growth utilizing Continus coggygria
TWI411448B (zh) 2007-12-27 2013-10-11 Avon Prod Inc 適合用於化妝品之光學模糊色素組合物
WO2010090988A2 (en) 2009-02-06 2010-08-12 The Procter & Gamble Company Collapsible water-containing capsules
US20100268335A1 (en) 2009-03-27 2010-10-21 Chunlin Yang Medical devices with galvanic particulates
US8258250B2 (en) 2009-10-07 2012-09-04 Johnson & Johnson Consumer Companies, Inc. Compositions comprising superhydrophilic amphiphilic copolymers and methods of use thereof
US8399590B2 (en) 2009-10-07 2013-03-19 Akzo Nobel Chemicals International B.V. Superhydrophilic amphiphilic copolymers and processes for making the same
US8545821B2 (en) 2009-11-05 2013-10-01 Avon Products, Inc. Cosmetic use of water-redispersible powders
US9793199B2 (en) 2009-12-18 2017-10-17 Ati Technologies Ulc Circuit board with via trace connection and method of making the same
US8647653B2 (en) * 2009-12-26 2014-02-11 Evonik Degussa Gmbh Water containing powder composition
KR20110091461A (ko) 2010-02-05 2011-08-11 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 갈바니 미립자를 포함하는 립 조성물
CN103025335A (zh) 2010-07-23 2013-04-03 强生消费者公司 产生腐蚀电流的金属颗粒及其用途
DE102011077298A1 (de) 2011-06-09 2012-12-13 Evonik Degussa Gmbh Kern-Hülle-Partikel mit einem hohen Gehalt an Glycerin, ihre Herstellung und Verwendung
DE102011088840A1 (de) 2011-12-16 2013-06-20 Henkel Ag & Co. Kgaa Pulverförmige Haarkosmetika
AU2013362950B2 (en) 2012-12-19 2017-04-13 Johnson & Johnson Consumer Companies, Inc. Anhydrous powder-to-liquid particles

Also Published As

Publication number Publication date
CA2943368C (en) 2022-03-15
CN110403833B (zh) 2022-05-24
BR112016022607B1 (pt) 2021-01-19
RU2016142479A (ru) 2018-05-03
US9474699B2 (en) 2016-10-25
EP3125857B1 (en) 2019-02-27
CA2943368A1 (en) 2015-10-08
CN110403833A (zh) 2019-11-05
CN106456476A (zh) 2017-02-22
WO2015153074A1 (en) 2015-10-08
RU2016142479A3 (pt) 2018-10-08
ES2719575T3 (es) 2019-07-11
RU2722783C2 (ru) 2020-06-03
EP3125857A1 (en) 2017-02-08
US20150272834A1 (en) 2015-10-01
CN106456476B (zh) 2019-08-27

Similar Documents

Publication Publication Date Title
BR112016022607B8 (pt) Pó e método para aprimorar a aplicação tópica de minoxidil
BR112016022159B8 (pt) Pó e método para melhorar a aplicação tópica de um agente de benefício ácido
BR112015014831A2 (pt) partículas anidras de pó a líquido
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112015023340A8 (pt) dispersões submicrômetras, substancialmente livres de tensoativo, de agentes hidrofóbicos contendo altos níveis de solvente miscível em água
IN2015MU00865A (pt)
MX2018006919A (es) Composiciones de emulsion inversas.
CA2934086C (en) Finisher composition comprising silicone microparticles and non-volatile oil
BR112015023321A2 (pt) dispersões submicrômetras substancialmente livres de surfactante e alimento com as mesmas
BR112015017405A2 (pt) composições que incluem agentes hidrofobizantes e estabilizantes e métodos para preparação e utilização das mesmas
BR112018074352A2 (pt) partículas de nanoalume contendo um agente de dimensionamento
PE20171334A1 (es) Formulacion en polvo nasal para el tratamiento de hipoglicemia
MA43918A (fr) Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
BR112017013484A2 (pt) processo para preparação de partículas de bicarbonato de metais alcalinos, partículas de bicarbonato de metal alcalino, e, usos de partículas de bicarbonato de metal alcalino e de um ácido de resina ou um ácido graxo ou uma cera.
BR112016015851A2 (pt) Formulações farmacêuticas estabilizadas de insulina aspart
BR112017004798A2 (pt) composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal
BR112018012952A2 (pt) composições para higiene pessoal
BR112016025126A2 (pt) formulação líquida compreendendo composto neutralizante de gm-csf
NZ732529A (en) Microencapsulated nitrification inhibitor compositions
BR112018011157A2 (pt) composição agroquímica de suspensão aquosa.
CL2018003110A1 (es) Preparación y dispersión de formulaciones de emulsión estable.
BR102015006886B8 (pt) Composição tópicas que compreendem 4-hexilresorcinol e pós e uso
BR112017024735A2 (pt) suspensão e emulsão de microcápsula e seu método de produção
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes
BR112016029317A2 (pt) composições e métodos para melhorar a aplicação tópica de um cosmético colorido

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: CHENANGO ZERO LLC (US)

B25A Requested transfer of rights approved

Owner name: CHENANGO TWO LLC (US)

B25A Requested transfer of rights approved

Owner name: CURRAHEE HOLDING COMPANY INC. (US)

B25D Requested change of name of applicant approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)

B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)

B25D Requested change of name of applicant approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)